Halifax, Canada
Halifax, Canada
SEARCH FILTERS
Time filter
Source Type

Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Market by Geography and Forecast to 2020, Published by iHealthcareAnalyst Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Market by Geography North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and Forecast 2016-2020. Maryland Heights, MO, February 27, 2017 --( Browse Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Market by Geography North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and Forecast 2016-2020 at https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/. Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a novel therapy for the treatment of hypervascuarized tumours. Through the intra-arterial delivery of microspheres, DEB-TACE allows for embolization as well as local release of chemotherapy in the treatment of hepatic malignancy, providing an alternative therapeutic option in unresectable tumours. Drug-eluting bead TACE is becoming more widely utilized in primary and liver-dominant metastatic disease of the liver. Microcatheters, are thin wall, small diameter catheters and delivery devices used in minimally invasive applications. These small catheters are ideal for navigating the vast network of tiny veins found within the body. Microcatheters are employed extensively in the neurovascular and cardiovascular fields. They are most commonly used in small vessel or selective diagnostic and interventional procedures, where an application requires an ultra-thin device for delivery, diagnosis, or mapping, a microcatheter is used. Radiopaque beads provide a practical solution for real time display of embolic material or drug delivery. These beads provide better conspicuity in determining the target during embolization and also allow optimal balance and delivery performance. The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report estimates the market size (Revenue USD million – 2013 to 2020) by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2016 to 2020). The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating the global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market and profiled in this report include Abbott Laboratories (Abbott EP), ABK Biomedical, Inc., Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Medtronic, Inc., Merit Medical Systems, Inc., Stryker Corporation, Surefire Medical, Inc., Terumo Corporation, and Vascular Solutions, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 27, 2017 --( PR.com )-- The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market is estimated to reach nearly USD 11.2 Billion in 2020, expanding at a CAGR of 8.6% from 2016 to 2020.Browse Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Market by Geography North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and Forecast 2016-2020 at https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/.Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a novel therapy for the treatment of hypervascuarized tumours. Through the intra-arterial delivery of microspheres, DEB-TACE allows for embolization as well as local release of chemotherapy in the treatment of hepatic malignancy, providing an alternative therapeutic option in unresectable tumours. Drug-eluting bead TACE is becoming more widely utilized in primary and liver-dominant metastatic disease of the liver. Microcatheters, are thin wall, small diameter catheters and delivery devices used in minimally invasive applications. These small catheters are ideal for navigating the vast network of tiny veins found within the body. Microcatheters are employed extensively in the neurovascular and cardiovascular fields. They are most commonly used in small vessel or selective diagnostic and interventional procedures, where an application requires an ultra-thin device for delivery, diagnosis, or mapping, a microcatheter is used. Radiopaque beads provide a practical solution for real time display of embolic material or drug delivery. These beads provide better conspicuity in determining the target during embolization and also allow optimal balance and delivery performance.The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report estimates the market size (Revenue USD million – 2013 to 2020) by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2016 to 2020). The global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating the global drug eluting beads, microcatheters and radiopaque beads in interventional oncology market and profiled in this report include Abbott Laboratories (Abbott EP), ABK Biomedical, Inc., Boston Scientific Corporation, BTG plc, Cook Medical, Inc., Medtronic, Inc., Merit Medical Systems, Inc., Stryker Corporation, Surefire Medical, Inc., Terumo Corporation, and Vascular Solutions, Inc.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/drug-eluting-beads-microcatheters-radiopaque-beads-interventional-oncology-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


Kehoe S.,ABK Biomedical | Looney M.,ABK Biomedical | Kilcup N.,Dalhousie University | Tonkopi E.,Interventional Imaging | And 8 more authors.
Journal of Non-Crystalline Solids | Year: 2014

Si-Ca-Zn-La-Ti-Mg-Sr-Na glasses have demonstrated excellent biocompatibility both in vitro using the MTT/LDH assays (with L929 mouse fibroblast cells and human blood platelets), and in vivo using New Zealand White rabbits. However, the biological evaluation of the materials was performed on as-manufactured glass granules that were autoclaved, rather than aged or γ-irradiated glass microspheres; the sterilization procedure required prior to implantation of these materials in its final form inside the human body. Given the fact that when a glass is subjected to aging either accelerated or natural changes in its physical properties can take place, it is imperative to determine whether the structure of such glasses will be altered over time in order to substantiate shelf-life claims. The structure of such glasses may also be altered as a result of exposure to the typical amounts of γ-irradiation required to sterilize such materials prior to implantation. This paper therefore examines the structure of Si-Ca-Zn-La-Ti-Mg-Sr-Na glasses using XRD, DSC, pycnometry, 29Si MAS-NMR and ICP-OES to evaluate both the effect of accelerated aging and multiple cycles of 30 kGy γ-irradiation on their structure and subsequent radiopacity. The 29Si MAS-NMR results indicate that the peak maxima for each glass remain between - 83 ppm and - 86 ppm; a chemical shift for 29Si associated with Q2 to Q3 units in silicate glasses, and that the local environment around the 29Si isotope remains unaltered as a result of aging or exposure. Additional analysis (XRD, DSC, pycnometry, ICP-OES and radiopacity) showed that the glass transition temperature, Tg (676 ± 4 °C) typically remains unchanged, as a result of exposure to both accelerated aging and ionizing radiation, as do the density (3.63 ± 0.02 g/cm3) radiopacity (7049 ± 847HU), chemical composition and XRD diffractograms for each glass. Therefore it can be concluded that the accelerated aging conditions tested herein or use of 30 kGy γ-irradiation dose or subsequent effects does not affect the local environment of the 29Si isotope in the glasses, nor does it significantly alter the XRD diffraction patterns, chemical composition, Tg, density or the radiopacity values for the glass composition (0.562Si-0.035Ca-0.188Zn-0.068La-0.042Ti-0.035 Mg-0.035Sr-0.035Na) described in this work. © 2014 Elsevier B.V.


PubMed | Interventional Imaging, ABK Biomedical and Dalhousie University
Type: Journal Article | Journal: Journal of biomaterials applications | Year: 2015

The purpose of this study was to synthesize and optimize intrinsically radiopaque composite embolic microspheres for sustained release of doxorubicin in drug-eluting bead transarterial chemoembolization. Using a design of experiments approach, 12 radiopaque composites composed of polylactic-co-glycolic acid and a radiopaque glass (ORP5) were screened over a range of compositions and examined for radiopacity (computed tomography) and density. In vitro cell viability was determined using an extract assay derived from each composition against the human hepatocellular carcinoma cell line, HepG2. Mathematical models based on a D-Optimal response surface methodology were used to determine the preferred radiopaque composite. The resulting radiopaque composite was validated and subsequently loaded with doxorubicin between 0 and 1.4% (wt% of polylactic-co-glycolic acid) to yield radiopaque composite drug-eluting beads. Thereafter, the radiopaque composite drug-eluting beads were subjected to an elution study (up to 168h) to determine doxorubicin release profiles (UV-Vis spectroscopy) and in vitro cell viability. Radiopaque composites evaluated for screening purposes had densities between 1.28 and 1.67g.cm(-3), radiopacity ranged between 211 and 1450HU and cell viabilities between 91 and 106% were observed. The optimized radiopaque composite comprised 23 wt% polylactic-co-glycolic acid and 60 wt% ORP5 with a corresponding density of 1.630.001g.cm(-3), radiopacity at 193044HU and cell viability of 897.6%. Radiopaque composite drug-eluting beads provided sustained doxorubicin release over 168h. In conclusion, the mathematical models allowed for the identification and synthesis of a unique radiopaque composite. The optimized radiopaque composite had similar density and cell viability to commercially available embolic microspheres. It was possible to preload doxorubicin into radiopaque composite drug-eluting beads, such that sustained release was possible under simulated physiological conditions.


Hasan M.S.,Dalhousie University | Kehoe S.,Dalhousie University | Boyd D.,Dalhousie University | Boyd D.,ABK Biomedical
Journal of Biomaterials Applications | Year: 2014

Embolization of vascular tumors is an important tool in minimally invasive surgical intervention. Radiopaque, non-degradable, and non-deformable spherical zinc-silicate glass particles were produced in a range of 45-500-μm. Three size ranges (45-150, 150-300, and 300-500-μm) were used in the current study. The glass microspheres were eluted in polar (saline solution) and non-polar (dimethyl sulfoxide) medium, and ion release profiles were recorded using inductively coupled plasma atomic emission spectroscopy. Approximately 80% of Gaussian distribution was achieved by simple sieving. The ions released from the microspheres were dependent upon surface area to volume ratio as well as the nature of elution media. Greater ions were released from smaller particles (45-150-μm) having largest surface area in polar medium. For the genotoxicity bacterial mutation Ames assay, the concentrations of all the ions were well below their therapeutic concentration reported in the literature. No mutagenic effect was observed in the bacterial mutation Ames test. Hence, it can be concluded that the glass microspheres produced herein are non-mutagenic further supporting the materials potential as a suitable embolic agent. © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.


PubMed | ABK Biomedical and Dalhousie University
Type: Journal Article | Journal: Journal of biomaterials applications | Year: 2014

Embolization of vascular tumors is an important tool in minimally invasive surgical intervention. Radiopaque, non-degradable, and non-deformable spherical zinc-silicate glass particles were produced in a range of 45-500m. Three size ranges (45-150, 150-300, and 300-500m) were used in the current study. The glass microspheres were eluted in polar (saline solution) and non-polar (dimethyl sulfoxide) medium, and ion release profiles were recorded using inductively coupled plasma atomic emission spectroscopy. Approximately 80% of Gaussian distribution was achieved by simple sieving. The ions released from the microspheres were dependent upon surface area to volume ratio as well as the nature of elution media. Greater ions were released from smaller particles (45-150m) having largest surface area in polar medium. For the genotoxicity bacterial mutation Ames assay, the concentrations of all the ions were well below their therapeutic concentration reported in the literature. No mutagenic effect was observed in the bacterial mutation Ames test. Hence, it can be concluded that the glass microspheres produced herein are non-mutagenic further supporting the materials potential as a suitable embolic agent.


ABK Biomedical | Entity website

Dr. Aaron Berez, MD ...


ABK Biomedical | Entity website

ABK Biomedical Inc. Innovative Embolic Therapies ...


Dr. Scott GoodwinDr ...


ABK Biomedical | Entity website

Occlu90Y OccluDEBABK Biomedicals radiopaque embolic bead platform includes drug eluting beads that continue the theme of inherent radiopacity set by OccluSystem. OccluDEB is engineered to deliver chemotherapy while occluding the vessels feeding a tumor, with a prime clinical application of liver cancer ...

Loading ABK Biomedical collaborators
Loading ABK Biomedical collaborators